The study demonstrates improved solubility and dissolution of azilsartan using liquisolid technique, indicating effective optimization methods.
The Liquisolid technique was employed to enhance the solubility and dissolution of Azilsartan, an angiotensin II receptorblocker with poor aqueous solubility. A 2² full factorial design was utilized to optimize the formulation parameters,particularly focusing on FUJ and Croscarmellose Sodium concentrations. Solubility studies conducted in non-volatilesolvents (Labrasol, Captisol, Transcutol HP, and Capryol) identified Labrasolas the most effective solvent (96.37±0.82mg/mL), while Fujicalin exhibited the highest solubility enhancement (0.42 ± 0.02 mg/mL) among different carriers.The optimized formulation, containing 50mg FUJ and 5% Croscarmellose Sodium, demonstrated significantly improveddrug release compared to the pure drug. FTIR analysis confirmed no significant drug-excipient interactions, ensuring thestability of the formulation. Pre-compression and post-compression parameters, including Carr’s Index (13.85 ± 0.30%),Hausner’s Ratio (1.16 ± 0.01), hardness (5.6 ± 0.2 kg/cm²), friability (0.78 ± 0.03%), and disintegration time (65.2 ± 2.1sec, n=3), confirmed the formulation’s suitability for tablet manufacturing. Stability studies conducted per ICH guidelinesdemonstrated that the optimized formulation remained stable for three months.The study confirms that the Liquisolidtechnique significantly improves the solubility and dissolution of Azilsartan.
No takes yet. Share an insight, caveat, or question.
Lavanya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: